Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases
C. Bernard, Delphine Maucort‐Boulch, Loig Varron et al. · QJM · 2013
AIM: To describe the main characteristics and the treatment of cryptococcosis in patients with sarcoidosis. DESIGN: Multicenter study including all patients notified at the French National Reference Center for Invasive Mycoses and Antifungals. METHODS: Retrospective chart review. Each case was compared with two controls without opportunistic infections. RESULTS: Eighteen cases of cryptococcosis complicating sarcoidosis were analyzed (13 men and 5 women). With 2749 cases of cryptococcosis registered in France during the inclusion period of this study, sarcoidosis accounted for 0.6% of all the cryptococcosis patients and for 2.9% of the cryptococcosis HIV-seronegative patients. Cryptococcosis and sarcoidosis were diagnosed concomitantly in four cases; while sarcoidosis was previously known in 14/18 patients, including 12 patients (67%) treated with steroids. The median rate of CD4 T cells was 145 per mm(3) (range: 55-1300) and not related to steroid treatment. Thirteen patients had cryptococcal meningitis (72%), three osteoarticular (17%) and four disseminated infections (22%). Sixteen patients (89%) presented a complete response to antifungal therapy. After a mean follow-up of 6 years, no death was attributable to cryptococcosis. Extra-thoracic sarcoidosis and steroids were independent risk factors of cryptococcosis in a logistic regression model adjusted with the sex of the patients. CONCLUSIONS: Cryptococcosis is a significant opportunistic infection during extra-thoracic sarcoidosis, which occurs in one-third of the cases in patients without any treatment; it is not associated to severe CD4 lymphocytopenia and has a good prognosis.
Cited by 50 works. doi:10.1093/qjmed/hct052
Authors
- C. Bernard
- Delphine Maucort‐Boulch
- Loig Varron
- Caroline Charlier
- Karine Sitbon
- N. Freymond
- Damien Bouhour
- A. Hot
- Alain‐Charles Masquelet
- Dominique Valeyre
- Nathalie Costedoat-Chalumeau
- Manuel Etienne
- Isabelle Gueit
- S. Jouneau
- Ph. Delaval
- Luc Mouthon
- Jean Pouget
- J. Serratrice
- F. Vaylet
References
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
- Statement on Sarcoidosis
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
- Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999
- Infections withCryptococcus neoformansin the Acquired Immunodeficiency Syndrome
- Sarcoidosis
- Clinical Characteristics of Patients in a Case Control Study of Sarcoidosis
- Neurologic Manifestations in Sarcoidosis
- Central nervous system sarcoidosisdiagnosis and management
- Cryptococcosis in Human Immunodeficiency Virus–Negative Patients in the Era of Effective Azole Therapy